121 related articles for article (PubMed ID: 37330079)
1. Construction of carboxymethyl chitosan-based nanoparticles of hypoxia response for co-loading doxorubicin and tanshinone IIA.
Lu M; Ma L; Li J; Li J; Tong M; Dai F; Song F; Zhang X; Qiu T
Int J Biol Macromol; 2023 Jul; 244():125362. PubMed ID: 37330079
[TBL] [Abstract][Full Text] [Related]
2. Preparation of Modified Chitosan-based Nanoparticles for Efficient Delivery of Doxorubicin and/or Cisplatin to Breast Cancer Cells.
Matalqah SM; Aiedeh K; Mhaidat NM; Alzoubi KH; Al-Husein BA
Curr Cancer Drug Targets; 2022; 22(2):133-141. PubMed ID: 35081892
[TBL] [Abstract][Full Text] [Related]
3. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles.
Duan J; Mansour HM; Zhang Y; Deng X; Chen Y; Wang J; Pan Y; Zhao J
Int J Pharm; 2012 Apr; 426(1-2):193-201. PubMed ID: 22274587
[TBL] [Abstract][Full Text] [Related]
4. Diselenide-crosslinked carboxymethyl chitosan nanoparticles for doxorubicin delivery: Preparation and in vivo evaluation.
Wang J; Liu J; Lu DQ; Chen L; Yang R; Liu D; Zhang B
Carbohydr Polym; 2022 Sep; 292():119699. PubMed ID: 35725216
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
6. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.
Zhang J; Li J; Shi Z; Yang Y; Xie X; Lee SM; Wang Y; Leong KW; Chen M
Acta Biomater; 2017 Aug; 58():349-364. PubMed ID: 28455219
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells.
Alinejad V; Hossein Somi M; Baradaran B; Akbarzadeh P; Atyabi F; Kazerooni H; Samadi Kafil H; Aghebati Maleki L; Siah Mansouri H; Yousefi M
Biomed Pharmacother; 2016 Oct; 83():229-240. PubMed ID: 27372407
[TBL] [Abstract][Full Text] [Related]
8. pH-responsive magnetic Fe
Liu Q; Tan Z; Zheng D; Qiu X
Int J Biol Macromol; 2023 Jan; 225():1182-1192. PubMed ID: 36423809
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of doxorubicin and interleukin-2 via chitosan based nanoparticles for enhanced antitumor efficacy.
Wu J; Tang C; Yin C
Acta Biomater; 2017 Jan; 47():81-90. PubMed ID: 27729232
[TBL] [Abstract][Full Text] [Related]
10. Synergistic breast tumor cell killing achieved by intracellular co-delivery of doxorubicin and disulfiram via core-shell-corona nanoparticles.
Tao X; Gou J; Zhang Q; Tan X; Ren T; Yao Q; Tian B; Kou L; Zhang L; Tang X
Biomater Sci; 2018 Jun; 6(7):1869-1881. PubMed ID: 29808221
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity.
Lages EB; Fernandes RS; Silva JO; de Souza ÂM; Cassali GD; de Barros ALB; Miranda Ferreira LA
Biomed Pharmacother; 2020 Dec; 132():110876. PubMed ID: 33113428
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-responsive folic acid conjugated glycol chitosan nanoparticle for enhanced tumor targeting treatment.
Jang EH; Shim MK; Kim GL; Kim S; Kang H; Kim JH
Int J Pharm; 2020 Apr; 580():119237. PubMed ID: 32201251
[TBL] [Abstract][Full Text] [Related]
13. Catechol-modified chitosan/hyaluronic acid nanoparticles as a new avenue for local delivery of doxorubicin to oral cancer cells.
Pornpitchanarong C; Rojanarata T; Opanasopit P; Ngawhirunpat T; Patrojanasophon P
Colloids Surf B Biointerfaces; 2020 Dec; 196():111279. PubMed ID: 32750605
[TBL] [Abstract][Full Text] [Related]
14. An oral bioactive chitosan-decorated doxorubicin nanoparticles/bacteria bioconjugates enhance chemotherapy efficacy in an in-situ breast cancer model.
Li J; Wen Q; Dai J; Wang B; Lu Y; Wu Z; Fan Y; Zeng F; Chen Y; Zhang Y; Chen R; Fu S
Int J Biol Macromol; 2024 May; 267(Pt 1):131428. PubMed ID: 38583834
[TBL] [Abstract][Full Text] [Related]
15. A new combination strategy to enhance apoptosis in cancer cells by using nanoparticles as biocompatible drug delivery carriers.
Kucuksayan E; Bozkurt F; Yilmaz MT; Sircan-Kucuksayan A; Hanikoglu A; Ozben T
Sci Rep; 2021 Jun; 11(1):13027. PubMed ID: 34158544
[TBL] [Abstract][Full Text] [Related]
16. Rational Design of Nanoparticles to Overcome Poor Tumor Penetration and Hypoxia-Induced Chemotherapy Resistance: Combination of Optimizing Size and Self-Inducing High Level of Reactive Oxygen Species.
Deng L; Feng Z; Deng H; Jiang Y; Song K; Shi Y; Liu S; Zhang J; Bai S; Qin Z; Dong A
ACS Appl Mater Interfaces; 2019 Sep; 11(35):31743-31754. PubMed ID: 31389686
[TBL] [Abstract][Full Text] [Related]
17. Chitosan/o-carboxymethyl chitosan nanoparticles for efficient and safe oral anticancer drug delivery: in vitro and in vivo evaluation.
Feng C; Wang Z; Jiang C; Kong M; Zhou X; Li Y; Cheng X; Chen X
Int J Pharm; 2013 Nov; 457(1):158-67. PubMed ID: 24029170
[TBL] [Abstract][Full Text] [Related]
18. Chitosan Immobilization on Bio-MOF Nanostructures: A Biocompatible pH-Responsive Nanocarrier for Doxorubicin Release on MCF-7 Cell Lines of Human Breast Cancer.
Abazari R; Mahjoub AR; Ataei F; Morsali A; Carpenter-Warren CL; Mehdizadeh K; Slawin AMZ
Inorg Chem; 2018 Nov; 57(21):13364-13379. PubMed ID: 30351060
[TBL] [Abstract][Full Text] [Related]
19. Development of anti-HER2-targeted doxorubicin-core-shell chitosan nanoparticles for the treatment of human breast cancer.
Naruphontjirakul P; Viravaidya-Pasuwat K
Int J Nanomedicine; 2019; 14():4105-4121. PubMed ID: 31239670
[No Abstract] [Full Text] [Related]
20. Hollow Mesoporous Silica Nanoparticles Gated by Chitosan-Copper Sulfide Composites as Theranostic Agents for the Treatment of Breast Cancer.
Niu S; Zhang X; Williams GR; Wu J; Gao F; Fu Z; Chen X; Lu S; Zhu LM
Acta Biomater; 2021 May; 126():408-420. PubMed ID: 33731303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
